Seres Therapeutics sells VOWST to Nestlé Health Science for $175m, eliminating debt and advancing lead product SER-155.

Seres Therapeutics has finalized the sale of its VOWST business to Nestlé Health Science for roughly $175 million. This transaction eliminates Seres' debt and allows for the advancement of its lead product, SER-155, targeting patients at high risk of bacterial infections. The company plans to explore SER-155 in additional populations and is also developing SER-147 for chronic liver disease patients. The sale extends Seres' financial resources into late 2025.

September 30, 2024
3 Articles

Further Reading